DiaMedica Therapeutics Inc
$ 5.77
-1.20%
02 Jun - close price
- Market Cap 310,907,000 USD
- Current Price $ 5.77
- High / Low $ 5.89 / 5.54
- Stock P/E N/A
- Book Value 0.88
- EPS -0.71
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.50 %
- ROE -0.86 %
- 52 Week High 10.42
- 52 Week Low 3.48
About
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
Analyst Target Price
$15.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-30 | 2025-11-12 | 2025-08-12 | 2025-05-13 | 2025-03-17 | 2024-11-13 | 2024-08-07 | 2024-05-08 | 2024-03-19 | 2023-11-13 | 2023-08-14 |
| Reported EPS | -0.1655 | -0.17 | -0.17 | -0.18 | -0.18 | -0.18 | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 | -0.16 |
| Estimated EPS | -0.1933 | -0.175 | -0.17 | -0.19 | -0.18 | -0.1725 | -0.15 | -0.16 | -0.16 | -0.14 | -0.13 | -0.18 |
| Surprise | 0.0278 | 0.005 | 0 | 0.01 | 0 | -0.0075 | 0 | 0.03 | 0.02 | 0 | 0.01 | 0.02 |
| Surprise Percentage | 14.3818% | 2.8571% | 0% | 5.2632% | 0% | -4.3478% | 0% | 18.75% | 12.5% | 0% | 7.6923% | 11.1111% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DMAC
2026-06-03 21:39:15
DiaMedica Therapeutics Inc. CFO and Secretary, Kellen Scott, was granted 162,000 stock options with an exercise price of $5.84 per share. These options, part of compensation rather than a market purchase, will vest 25% after one year and the remainder in twelve quarterly installments, expiring on June 1, 2036. This transaction is noted as neutral impact and sentiment, increasing Scott's derivative holdings to 162,000 options.
2026-06-03 21:39:14
DiaMedica Therapeutics (DMAC) director Randall Michael Giuffre was granted 40,412 stock options at an exercise price of $5.84 per share. These options are for Voting Common Shares, expire on June 1, 2036, and will vest in four equal quarterly installments. This transaction was reported via a Form 4 filing and is compensation-related, not an open-market trade.
2026-06-03 21:39:14
DiaMedica Therapeutics Inc. director Daniel J. O'Connor was granted stock options for 40,412 voting common shares with an exercise price of $5.84 per share. These options expire on June 1, 2036, and will vest in four equal quarterly installments. Following this award, O'Connor directly holds options for 40,412 shares.
2026-06-03 21:39:14
DiaMedica Therapeutics director James T. Parsons was granted 51,189 stock options with an exercise price of $5.84 per share, expiring on June 1, 2036. This grant is a compensation-related award, not an open-market purchase, and is set to vest in four equal quarterly installments. The transaction was reported on a Form 4 SEC filing, detailing the award and its vesting schedule.
2026-06-01 20:11:09
DiaMedica's Q4 2025 earnings call highlighted a strong cash position, with $59.9 million in cash, cash equivalents, and short-term investments, expected to fund operations through 2027. The company reported significant progress in its DM199 preeclampsia program, showing dose-dependent blood pressure reductions and no placental barrier crossing, leading to regulatory clearance for a global Phase II trial. The ReMEDy2 stroke trial is also advancing, with nearly 70% enrollment for interim analysis and a positive safety review from the DSMB, with results expected in the second half of 2026.
2026-05-28 04:10:03
DiaMedica Therapeutics Inc. announced its participation in the 2026 Jefferies Global Healthcare Conference in New York. The clinical-stage biopharmaceutical company will deliver a corporate presentation on Thursday, June 4, 2026, at 3:45 PM ET. DiaMedica focuses on developing treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, with its lead candidate DM199 being a recombinant form of the KLK1 protein.
